[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492
[2] ARNOLD M, SOERJOMATARAM I, FERLAY J, et al. Global incidence of esophageal cancer by histological subtype in 2012[J]. Gut, 2015, 64(3): 381. doi: 10.1136/gutjnl-2014-308124
[3] ENZINGER PC, MAYER RJ. Esophageal cancer[J]. N Engl J Med, 2003, 349(23): 2241. doi: 10.1056/NEJMra035010
[4] GRIVENNIKOV SI, GRETEN FR, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883. doi: 10.1016/j.cell.2010.01.025
[5] KIM S, HAN S, AZAM T, et al. Interleukin-32: a cytokine and inducer of TNF-α[J]. Immunity, 2005, 22(1): 131.
[6] HEINHUIS B, PLANTINGA TS, SEMANGO G, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines[J]. Carcinogenesis, 2016, 37(2): 197. doi: 10.1093/carcin/bgv172
[7] LEE YS, KIM KC, MONGRE RK, et al. IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway[J]. Cell Death Dis, 2019, 10(7): 506. doi: 10.1038/s41419-019-1737-4
[8] DONNEM T, HU J, FERGUSON M, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?[J]. Cancer Med, 2013, 2(4): 427. doi: 10.1002/cam4.105
[9] HANAHAN D, WEINBERG RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646. doi: 10.1016/j.cell.2011.02.013
[10] YUN J, PARK MH, SON DJ, et al. IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation[J]. Cell Death Dis, 2018, 9(3): 306. doi: 10.1038/s41419-018-0375-6
[11] BHAT S, GARDI N, HAKE S, et al. Impact of intra-tumoral IL17A and IL32 gene expression on T cell responses and lymph node status in breast cancer patients[J]. Cancer Res Clin Oncol, 2017, 143(9): 1745. doi: 10.1007/s00432-017-2431-5
[12] HONG JT, SON DJ, LEE CK, et al. Interleukin 32, inflammation and cancer[J]. Pharmacol Therapeut, 2017, 174: 127. doi: 10.1016/j.pharmthera.2017.02.025
[13] JOOSTEN LA, HEINHUIS B, NETEA MG, et al. Novel insights into the biology of interleukin-32[J]. Cell Mol Life Sci, 2013, 70(20): 3883. doi: 10.1007/s00018-013-1301-9
[14] HEINHUIS B, KOENDERS MI, VANDENBERG WB, et al. Interleukin 32(IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1[J]. J Biol Chem, 2012, 287(8): 5733. doi: 10.1074/jbc.M111.288290
[15] OH JH, CHO MC, KIM JH, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals[J]. Oncogene, 2011, 30(30): 3345. doi: 10.1038/onc.2011.52
[16] WANG M, MENG B, LIU Y, et al. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3[J]. Cell Physiol Biochem, 2017, 44(5): 2017. doi: 10.1159/000485907
[17] ZHANG Q, ZHANG C, HE J, et al. STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma[J]. Tumor Biol, 2015, 36(3): 2135. doi: 10.1007/s13277-014-2823-y
[18] 袁宁, 吴佗, 侯佩强, 等. 急性白血病患者血清中IL-32的表达及其临床意义[J]. 中华血液学杂志, 2015, 36(10): 868. doi: 10.3760/cma.j.issn.0253-2727.2015.10.014